Quinlan Paul T 4

What Happened
Paul T. Quinlan, General Counsel of Oruka Therapeutics, sold 733 shares on 2026-06-15 at $69.69 per share, generating proceeds of $51,083. The sale was a disposal (S) reported as being effected through the company's automatic sell-to-cover procedure to satisfy tax withholding tied to the vesting of restricted stock units — a routine administrative transaction rather than an investment decision.

Key Details

• Transaction date: 2026-06-15
• Transaction type: Sale (S), 733 shares @ $69.69 per share; total ≈ $51,083
• Sale method: Reported as open-market/private sale, effected via Oruka’s automatic, non-discretionary sell-to-cover for tax withholding (Footnote F1)
• Shares owned after transaction: Not specified in the provided filing summary
• Filing date / Period of report: Filed 2026-06-15 for period 2026-06-15 — appears timely based on provided data

Context
Sell-to-cover transactions are common when restricted stock units vest and taxes are due; they typically reflect tax withholding, not a deliberate vote of no confidence in the company. For retail investors, purchases or non-routine sales by insiders can be more informative about insider sentiment than routine tax-related disposals.